Literature DB >> 18240019

Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer.

Kirsimari Aaltonen1, Rose-Marie Amini, Göran Landberg, Hannaleena Eerola, Kristiina Aittomäki, Päivi Heikkilä, Heli Nevanlinna, Carl Blomqvist.   

Abstract

Cyclins D1 and E play an important role in breast carcinogenesis. High cyclin E expression is common in hormone receptor negative and high grade aggressive breast cancer, whereas cyclin D1 in hormone receptor positive and low grade breast cancer. Experimental data has suggested that cyclin D1 and E mediate cell proliferation by different mechanisms in estrogen receptor (ER) positive and negative breast cancer. To test this hypotheses in large breast cancer material and to clarify the histopathological correlations of cyclin E and D1, especially the association with proliferation, we analyzed cyclin E and D1 immunohistochemical expression on breast tumour microarrays consisting of 1348 invasive breast cancers. High cyclin D1 expression was associated with high grade (P<0.0005), high cyclin A (P<0.0005) and Ki67 (P<0.0005) expression among ER positive but with low grade (P=0.05) and low Ki67 (P=0.01) expression among ER negative breast cancers. Cyclin E and D1 expression correlated positively in ER positive (P<0.0005) but had a negative correlation in ER negative tumours (P=0.004). Cyclin E associated with high grade among all tumours (P<0.0005). In conclusion, the findings of this study show that cyclin D1 has separate roles, and proliferation is driven by different mechanisms in ER positive and negative breast cancers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18240019     DOI: 10.1007/s10549-008-9908-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  26 in total

1.  The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway.

Authors:  M Carla Cabrera; Edgar S Díaz-Cruz; Bhaskar V S Kallakury; Michael J Pishvaian; Clinton J Grubbs; Donald D Muccio; Priscilla A Furth
Journal:  Cancer Prev Res (Phila)       Date:  2012-04-16

2.  Expression pattern of ATM and cyclin D1 in ductal carcinoma, normal adjacent and normal breast tissues of Iranian breast cancer patients.

Authors:  Mahdieh Salimi; Hossein Mozdarani; Keivan Majidzadeh
Journal:  Med Oncol       Date:  2011-08-18       Impact factor: 3.064

3.  Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.

Authors:  Richard S P Huang; Xinyan Li; James Haberberger; Ethan Sokol; Eric Severson; Daniel L Duncan; Amanda Hemmerich; Claire Edgerly; Erik Williams; Julia Elvin; Jo-Anne Vergilio; Jonathan Keith Killian; Douglas Lin; Matthew Hiemenz; Jinpeng Xiao; Deborah McEwan; Oliver Holmes; Natalie Danziger; Rachel Erlich; Garrett Frampton; Michael B Cohen; Kimberly McGregor; Prasanth Reddy; Dawn Cardeiro; Rachel Anhorn; Jeffrey Venstrom; Brian Alexander; Charlotte Brown; Lajos Pusztai; Jeffrey S Ross; Shakti H Ramkissoon
Journal:  Oncologist       Date:  2020-09-14

4.  RNA sequencing of MCF-7 breast cancer cells identifies novel estrogen-responsive genes with functional estrogen receptor-binding sites in the vicinity of their transcription start sites.

Authors:  Ryonosuke Yamaga; Kazuhiro Ikeda; Kuniko Horie-Inoue; Yasuyoshi Ouchi; Yutaka Suzuki; Satoshi Inoue
Journal:  Horm Cancer       Date:  2013-03-23       Impact factor: 3.869

5.  Fruit and vegetable intake and risk of breast cancer by hormone receptor status.

Authors:  Seungyoun Jung; Donna Spiegelman; Laura Baglietto; Leslie Bernstein; Deborah A Boggs; Piet A van den Brandt; Julie E Buring; James R Cerhan; Mia M Gaudet; Graham G Giles; Gary Goodman; Niclas Hakansson; Susan E Hankinson; Kathy Helzlsouer; Pamela L Horn-Ross; Manami Inoue; Vittorio Krogh; Marie Lof; Marjorie L McCullough; Anthony B Miller; Marian L Neuhouser; Julie R Palmer; Yikyung Park; Kim Robien; Thomas E Rohan; Stephanie Scarmo; Catherine Schairer; Leo J Schouten; James M Shikany; Sabina Sieri; Schoichiro Tsugane; Kala Visvanathan; Elisabete Weiderpass; Walter C Willett; Alicja Wolk; Anne Zeleniuch-Jacquotte; Shumin M Zhang; Xuehong Zhang; Regina G Ziegler; Stephanie A Smith-Warner
Journal:  J Natl Cancer Inst       Date:  2013-01-24       Impact factor: 13.506

6.  Evaluation of CCND1 amplification and CyclinD1 expression: diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers.

Authors:  Zhishuang Li; Jingjing Cui; Qiong Yu; Xiaojuan Wu; Aifeng Pan; Li Li
Journal:  Am J Transl Res       Date:  2016-01-15       Impact factor: 4.060

7.  No difference in CCND1 gene expression between breast cancer patients with and without lymph node metastasis in a Southern Brazilian sample.

Authors:  L B L Maia; F S C Breginski; T C S Cavalcanti; R L R de Souza; V M S Roxo; E M S F Ribeiro
Journal:  Clin Exp Med       Date:  2015-09-26       Impact factor: 3.984

8.  CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin.

Authors:  Elizabeth Tarasewicz; Randala Hamdan; Joelle Straehla; Ashley Hardy; Omar Nunez; Stanislav Zelivianski; Danijela Dokic; Jacqueline S Jeruss
Journal:  Cancer Biol Ther       Date:  2014-07-09       Impact factor: 4.742

9.  Cell Cycle Protein Expression in Neuroendocrine Tumors: Association of CDK4/CDK6, CCND1, and Phosphorylated Retinoblastoma Protein With Proliferative Index.

Authors:  Yan Shi; Zhi Rong Qian; Sui Zhang; Wanwan Li; Yohei Masugi; Tingting Li; Jennifer A Chan; Juhong Yang; Annacarolina Da Silva; Mancang Gu; Li Liu; Tsuyoshi Hamada; Keisuke Kosumi; Trevor Dutton; Lauren K Brais; Reiko Nishihara; Charles S Fuchs; Shuji Ogino; Matthew H Kulke
Journal:  Pancreas       Date:  2017 Nov/Dec       Impact factor: 3.327

10.  Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factors.

Authors:  Pia Boström; Mirva Söderström; Tuire Palokangas; Tero Vahlberg; Yrjö Collan; Olli Carpen; Pirkko Hirsimäki
Journal:  BMC Res Notes       Date:  2009-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.